Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8

Benzinga · 2d ago
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.